RFA-MD-23-002: Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on September 6, 2023.
From the official notice on Grants.gov, last changed January 31, 2023. Checked November 7, 2026.
- Award ceiling$295,924
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsOptional
- Funded byNIMHD
- Median yearly award$295,186
- Typical project length1.5 years
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under RFA-MD-23-002 were run by National Institute on Minority Health and Health Disparities (NIMHD, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-MD-23-002 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-MD-24-007 | March 8, 2024 | Closed November 17, 2025 | Closed |
| RFA-MD-22-003 | January 5, 2022 | Closed April 4, 2022 | Closed |
| RFA-MD-21-005 | March 11, 2021 | Closed May 3, 2021 | Closed |
Key dates
| Posted | January 30, 2023 |
|---|---|
| Deadline | September 6, 2023 |
| Archived by Grants.gov | October 12, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $295,186; it allows up to $295,924 per award.
- Most of the money in the 4 programs behind this notice (78% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations experiencing health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.
Funded under RFA-MD-23-002 so far
NIH funded 4 projects under RFA-MD-23-002 in fiscal 2024 to 2025, at 4 institutions. The median yearly award was $295,186.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| MiREA, a mHealth intervention to Reduce Health Disparities by Improving Access to Mandated College Students with Problematic Alcohol and Marijuana Use | Mhealth Systems, Inc | 2025 | $296,519 |
| Achieving health equity through food as medicine and medically tailored meals: local economic opportunity | Equiti Foods, LLC | 2024 | $295,923 |
| A Biobased Biodegradable Sunscreen that is Safe, Removes Environmental Impact, is Inclusive of all Skin Tones, and is for the Purpose of Eliminating Disparities in Melanoma Mortality Rates | Olipha Inc | 2024 | $293,629 |
| Addressing health disparities through a quantitative physiological database and precision systems modeling | Precision Quantomics Inc | 2024 | $294,450 |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Who has won Minority Health and Health Disparities Research grants before
From fiscal 2021 to 2025, Minority Health and Health Disparities Research (93.307) awarded $2.0 billion across 1,237 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 37 | $69.3 million |
| The Trustees of Columbia University in the City of New York | New York | 25 | $59.1 million |
| University of Hawaii | Hawaii | 18 | $52.8 million |
| The Regents of the University of California, San Francisco | California | 24 | $49.5 million |
| The Morehouse School of Medicine, Inc. | Georgia | 4 | $44.1 million |
Other programs behind this notice
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-MD-23-002 still open?
No. It closed on September 6, 2023.
Who can apply for Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)?
Closed September 6, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $295,924 each.
Who has been funded under RFA-MD-23-002?
NIH RePORTER lists 4 projects funded under RFA-MD-23-002 in fiscal 2024 to 2025, at 4 institutions. The most were at Mhealth Systems, Inc, Equiti Foods, LLC, Olipha Inc.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)